sydney meeting, page-24

Jessie,
I certainly object strongly to political tea parties. Investor briefings should be factual and open to ASX.
These political tea parties are held to appease aggrieved shareholders and each of the loosely thrown "ideas" need not be tested against actual facts.

Let me debunk each of the PC "ideas" so that every HC readers can form their own opinion of PC.

PC Idea Number 1:
Jessie: "He was interested in the concept being described by PC of some sort of strategic acquisition or partnership encompassing a near term product in order to "smooth" the pipeline. PC used the word "smooth" to describe the idea of having trailing products that come online every 18 months or so"

Answer:
FACTS: Peter Cook spend 5 years as CEO doing NOTHING to advance LANI trials in ROW. Relenza patents run out in the US in 2014 and LANI is not ready for ROW market until at least after 2016. Peter Cook's performance here to smooth the pipeline with trailing products coming on line speak for itself.

PC Idea Number 2:
Quoting Esc: I think the reason given by PC that big pharmas do not like influenza antiviral products is that flu antiviral product market is very unstable and hence unpredictable, and big pharmas like more predictable markets.


Answers:
Quoting mjmj: We have a product that could & should grab a big share of a billion dollar annual market over the next three years. Or is Tamiflu resistance a myth? Is 50:50 stockpiling rebalancing a myth? Is the normalised relationship with GSK myth?

Quoting Peter Cook when he asked shareholders to reward him free oopies:
I also want to acknowledge here the very visible marketing changes GSK has brought to their influenza franchise since the appointment of Andrew Witty as their CEO. GSK has made major changes to its marketing approach in this sector.
Notwithstanding the near term unpredictability of the how the current swine flu pandemic plays out in the current northern hemisphere winter season,Relenza should see larger volumes, more stable year on year take-off and improved market share over the medium to long term, compared to what we have seen in the past.

The Pandemic market is hundreds times the annual seasonal flu and it is unstable and unpredictable. However the annual market for flu antiviral is worth a Billion dollars and to state Big Pharmas are not insterested is mind boggling. This is perhaps best reflected by Peter cook's tenure as the CEO of Orbital Engine (OEC) where OEC share price dropped by almost 80%. OEC has the technology to make internal combustion engines leaner and meaner and oil prices were sky-rocketing, there was growing concern with global warming. OEC shareholders misfortune were reflected in the dwindling share price against an ever increasing ASX index.

To state now that the unstable and unpredictable Pandemic sales is detrimental to getting Big Pharmas interested in antiviral is at best misguided.


MORE TO FOLLOW.